Due to a high workload volume and ensuring submissions are reviewed in a timely manner, CADTH is deferring the effective date of the following two CDR procedural revisions: The timing of CDR review team’s responses being provided to the manufacturer, and The revised CDR voluntary withdrawal procedure The revised date for these two ...
Minimum Period of 120 Calendar Days for Advance Notification of Anticipated Submissions and Resubmissions for CADTH’s CDR and pCODR Programs
Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs In collaboration with the participating jurisdictions and with input from stakeholders, CADTH has established a single recommendation framework to support the drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert ...
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 11, 2016 for Hospira HealthCare Corporation’s subsequent entry biologic (SEB), INFLECTRA™ (infliximab). According to the CADTH website, Hospira is seeking public reimbursement for Crohn’s disease and Ulcerative Colitis. For those interested in providing ...
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, 2016 for etanercept - the subsequent entry biologic (SEB) version of Amgen’s ENBREL™. For those interested in providing patient input, please complete the CDR Patient Input Submission. According to the ...
Update on Procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: Mandatory Disclosure of a Submitted Drug Price
Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ...
New Pilot Initiative: Increasing Opportunities for Clinical Input and Feedback in CADTH pan-Canadian Oncology Drug Review Process
In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback ...
CADTH is currently updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. To help with this initiative, CADTH is inviting interested stakeholders to provide input. These guidelines detail best practices for conducting economic evaluations and are used to standardize and facilitate economic evaluations while ...
As requested by stakeholders, the deadline for the following CADTH calls for stakeholder input has been extended to November 9, 2015 at 5:00 p.m. EST: CDR Update – Issue 111 CADTH Consultation: Revisions to the Common Drug Review Procedure Invites stakeholder comments and feedback on the following proposed revisions to the Procedure ...
Expanding the CADTH Drug Review Process to Receive Patient Input Submissions from Individual Patients and Caregivers
Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately. Please note that for ...
CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month. Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation. For ...